Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, 

Who Bring Deep, Relevant Experience in Life Sciences

Mr. Patel and Dr. Senderowicz to Stand for Election at 2026 Annual Meeting with Independent Directors

Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger and Dr. Claus van der Velden

Urges Stockholders to Reject Attempt by PVG Asset Management Corporation and Patrick S. Adams to Acquire Control of the Company

Issues Open Letter to Stockholders and Files Preliminary Proxy Statement

NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system ("CNS") diseases with high unmet medical needs, today announced that the Executive Committee of the Company’s Board of Directors (the "Executive Committee") has taken significant steps to continue overseeing critical progress to enhance stockholder value.